Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-098456
Filing Date
2024-11-14
Accepted
2024-11-14 16:15:52
Documents
30
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0220551-10q_raphael.htm   iXBRL 10-Q 262742
2 CERTIFICATION ea022055101ex31-1_raphael.htm EX-31.1 11825
3 CERTIFICATION ea022055101ex31-2_raphael.htm EX-31.2 11735
4 CERTIFICATION ea022055101ex32-1_raphael.htm EX-32.1 3624
5 CERTIFICATION ea022055101ex32-2_raphael.htm EX-32.2 3486
  Complete submission text file 0001213900-24-098456.txt   1357230

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE raph-20240930.xsd EX-101.SCH 11513
7 XBRL CALCULATION FILE raph-20240930_cal.xml EX-101.CAL 12521
8 XBRL DEFINITION FILE raph-20240930_def.xml EX-101.DEF 51757
9 XBRL LABEL FILE raph-20240930_lab.xml EX-101.LAB 126128
10 XBRL PRESENTATION FILE raph-20240930_pre.xml EX-101.PRE 68256
32 EXTRACTED XBRL INSTANCE DOCUMENT ea0220551-10q_raphael_htm.xml XML 72347
Mailing Address SUITE 105 - 5348 VEGAS DR. LAS VEGAS NV 89108
Business Address SUITE 105 - 5348 VEGAS DR. LAS VEGAS NV 89108 702-442-1166
Raphael Pharmaceutical Inc. (Filer) CIK: 0001415397 (see all company filings)

EIN.: 260204284 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-53002 | Film No.: 241462555
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)